Antibody induction of lymphocyte-mediated cytotoxicity against human transitional-cell carcinomas of the urinary tract.
D000230:Adenocarcinoma / Q000276:immunology; D000917:Antibody Formation; D000951:Antigens, Neoplasm; D002295:Carcinoma, Transitional Cell / Q000276:immunology*; D002351:Carrageenan / Q000494:pharmacology; D002470:Cell Survival; D002845:Chromatography; D003169:Complement Inactivator Proteins; D003601:Cytotoxicity Tests, Immunologic; D004622:Embryo, Mammalian; D005260:Female; D006801:Humans; D007106:Immune Sera; D007074:Immunoglobulin G / Q000032:analysis; D007668:Kidney / Q000276:immunology; D007680:Kidney Neoplasms / Q000276:immunology; D007682:Kidney Pelvis; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D009132:Muscles / Q000276:immunology; D012867:Skin / Q000276:immunology; D013737:Testis / Q000276:immunology; D014516:Ureteral Neoplasms / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000276:immunology; D014565:Urogenital Neoplasms / Q000276:immunology*
D000951:Antigens, Neoplasm; D003169:Complement Inactivator Proteins; D007106:Immune Sera; D007074:Immunoglobulin G; D002351:Carrageenan